nach oben

Neurological Sciences

Erschienen in:

20.06.2022 | Review Article

The ultimate guide to the anti-CGRP monoclonal antibodies galaxy

verfasst von: Davide Mascarella, Eleonora Matteo, Valentina Favoni, Sabina Cevoli

Erschienen in: Neurological Sciences | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Anti-CGRP monoclonal antibodies have represented a real revolution in the field of headaches, being the result of an extraordinary process of translation of new pathophysiological discoveries into successful therapies. Nonetheless, clinical practice is far more complex than pivotal trials setting, and real-world studies are blooming to deepen knowledge of these revolutionary medications.

Objective

To provide an updated guide for evidence-based clinical practice.

Methods

Pivotal phase 3 randomised clinical trials for each anti-CGRP(-R) monoclonal antibody were considered. We evaluated prospective real-world studies and summarised evidence on anti-CGRP mAbs use beyond episodic and chronic migraine.

Results

All phase 3 RCTs showed an unprecedented profile of efficacy and safety in migraine prevention for the four anti-CGRP mAbs. However, plenty of questions remained open after the approval process. Real-world studies filled the gap and effectiveness results equalled or unexpectedly outperformed RCTs figures in most cases; safety results showed a lower incidence of adverse events, but a higher frequency of reported constipation compared to RCTs. Almost all studies displayed a rapid and progressive headache worsening following treatment suspension. Several positive response predictors were suggested, such as unilateral pain, allodynia in episodic migraineurs, response to triptans, and a lower number of failed prophylaxes. Comparable effectiveness was observed in resistant/refractory patients. In medication overuse headache patients, a clear clinical benefit was observed irrespective of any possible detoxification program.

Conclusions

Our narrative review restates the remarkable efficacy, effectiveness, and safety profile in both RCTs and real-world settings and provides scientific evidence for clinical practice.

Edvinsson L, finestra C a un sito esterno I contenuti a cui indirizza il collegamento verranno aperti in una nuova, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neuro 14(6):338-350

Migraine AM (2020) N Engl J Med 383(19):1866–1876. https://doi.org/10.1056/NEJMra1915327CrossRef

Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L (2010) Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 169(2):683–696. https://doi.org/10.1016/j.neuroscience.2010.05.016CrossRefPubMed

Lundblad C, Haanes KA, Grände G, Edvinsson L (2015) Experimental inflammation following dural application of complete Freund’s adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage. J Headache Pain 16(1):91. https://doi.org/10.1186/s10194-015-0575-8CrossRefPubMedPubMedCentral

Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28(2):183–187. https://doi.org/10.1002/ana.410280213CrossRefPubMed

Hansen JM, Hauge AW, Olesen J, Ashina M (2010) Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 30(10):1179–1186. https://doi.org/10.1177/0333102410368444CrossRefPubMed

Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298(5871):240–244. https://doi.org/10.1038/298240a0CrossRefPubMed

Edvinsson L (2007) Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists. Expert Opin Ther Targets 11(9):1179–1188. https://doi.org/10.1517/14728222.11.9.1179CrossRefPubMed

Goadsby PJ, Reuter U, Hallström Y et al (2020) One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. Neurology 95(5):e469–e479. https://doi.org/10.1212/WNL.0000000000010019CrossRefPubMedPubMedCentral

10.

Dodick DW, Ashina M, Brandes JL et al (2018) ARISE: A phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026–1037. https://doi.org/10.1177/0333102418759786CrossRefPubMed

11.

Reuter U, Goadsby PJ, Lanteri-Minet M et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. The Lancet 392(10161):2280–2287. https://doi.org/10.1016/S0140-6736(18)32534-0CrossRef

12.

Goadsby PJ, Reuter U, Lanteri-Minet M et al (2021) Long-term efficacy and safety of erenumab: results from 64 weeks of the LIBERTY study. Neurology 96(22):e2724–e2735. https://doi.org/10.1212/WNL.0000000000012029CrossRefPubMedCentral

13.

Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434. https://doi.org/10.1016/S1474-4422(17)30083-2CrossRefPubMed

14.

Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080. https://doi.org/10.1001/jamaneurol.2018.1212CrossRefPubMedPubMedCentral

15.

Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442–1454. https://doi.org/10.1177/0333102418779543CrossRefPubMed

16.

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211–e2221. https://doi.org/10.1212/WNL.0000000000006640CrossRefPubMedPubMedCentral

17.

Mulleners WM, Kim BK, Láinez MJA et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet Neurology. 19(10):814–825. https://doi.org/10.1016/S1474-4422(20)30279-9CrossRefPubMed

18.

Dodick DW, Silberstein SD, Bigal ME et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999. https://doi.org/10.1001/jama.2018.4853CrossRefPubMed

19.

Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113–2122. https://doi.org/10.1056/NEJMoa1709038CrossRefPubMed

20.

Ferrari MD, Diener HC, Ning X et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet 394(10203):1030–1040. https://doi.org/10.1016/S0140-6736(19)31946-4CrossRef

21.

Ashina M, Saper J, Cady R et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241–254. https://doi.org/10.1177/0333102420905132CrossRefPubMedPubMedCentral

22.

Lipton RB, Goadsby PJ, Smith J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365–e1377. https://doi.org/10.1212/WNL.0000000000009169CrossRefPubMedPubMedCentral

23.

Lipton RB, Cohen JM, Bibeau K et al (2020) Reversion from chronic migraine to episodic migraine in patients treated with fremanezumab: post hoc analysis from HALO CM study. Headache J Head Face Pain 60(10):2444–2453. https://doi.org/10.1111/head.13997CrossRef

24.

Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21(1):114. https://doi.org/10.1186/s10194-020-01173-8CrossRefPubMedPubMedCentral

25.

Tepper SJ, Diener HC, Ashina M et al (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92(20):e2309–e2320. https://doi.org/10.1212/WNL.0000000000007497CrossRefPubMedPubMedCentral

26.

Lipton RB, Burstein R, Buse DC et al (2021) Efficacy of erenumab in chronic migraine patients with and without ictal allodynia. Cephalalgia 41(11–12):1152–1160. https://doi.org/10.1177/03331024211010305CrossRefPubMed

27.

Barbanti P, Aurilia C, Egeo G et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache J Head Face Pain 61(2):363–372. https://doi.org/10.1111/head.14032CrossRef

28.

Barbanti P, Aurilia C, Cevoli S et al (2021) Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache J Head Face Pain 61(9):1351–1363. https://doi.org/10.1111/head.14194CrossRef

29.

for the GARLIT Study Group, Vernieri F, Altamura C et al (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35. https://doi.org/10.1186/s10194-021-01247-1CrossRef

30.

de Vries LS, Verhagen IE, van den Hoek TC, MaassenVanDenBrink A, Terwindt GM (2021) Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study. Eur J Neurol 28(12):4194–4203. https://doi.org/10.1111/ene.15075CrossRef

31.

Belvís R, Irimia P, Pozo-Rosich P et al (2021) MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention. J Headache Pain 22(1):74. https://doi.org/10.1186/s10194-021-01267-xCrossRefPubMedPubMedCentral

32.

Schoenen J, Timmermans G, Nonis R, Manise M, Fumal A, Gérard P (2021) Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes. Front Neurol 12:805334. https://doi.org/10.3389/fneur.2021.805334CrossRefPubMedPubMedCentral

33.

Torres-Ferrús M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 268(10):3789–3798. https://doi.org/10.1007/s00415-021-10523-8CrossRefPubMed

34.

Cheng S, Jenkins B, Limberg N, Hutton E (2020) Erenumab in chronic migraine: an Australian experience. Headache J Head Face Pain 60(10):2555–2562. https://doi.org/10.1111/head.13968CrossRef

35.

Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61. https://doi.org/10.1186/s10194-020-01127-0CrossRefPubMedPubMedCentral

36.

Pensato U, Baraldi C, Favoni V et al (2022) Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci 43(2):1273–1280. https://doi.org/10.1007/s10072-021-05426-5CrossRefPubMed

37.

Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (2021) Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain 22(1):120. https://doi.org/10.1186/s10194-021-01328-1CrossRefPubMedPubMedCentral

38.

Boudreau GP (2020) Treatment of chronic migraine with erenumab alone or as an add on therapy: a real-world observational study. Anesth Pain Res. 4(1). https://doi.org/10.33425/2639-846X.1037

39.

Barbanti P, Egeo G, Aurilia C et al (2022) Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain 23(1):46. https://doi.org/10.1186/s10194-022-01396-xCrossRefPubMedPubMedCentral

40.

Kuruppu DK, North JM, Kovacik AJ, Dong Y, Pearlman EM, Hutchinson SL (2021) Onset, maintenance, and cessation of effect of galcanezumab for prevention of migraine: a narrative review of three randomized placebo-controlled trials. Adv Ther 38(3):1614–1626. https://doi.org/10.1007/s12325-021-01632-xCrossRefPubMedPubMedCentral

41.

Vernieri F, Brunelli N, Messina R et al (2021) Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain 22(1):154. https://doi.org/10.1186/s10194-021-01363-yCrossRefPubMedPubMedCentral

42.

Guerzoni S, Baraldi C, Pensato U, et al (2022) Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. Neurol Sci. Published online https://doi.org/10.1007/s10072-022-05870-x

43.

Raffaelli B, Terhart M, Overeem LH et al (2022) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia 42(4–5):326–334. https://doi.org/10.1177/03331024211046617CrossRefPubMed

44.

Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Predictors of sustained response and effects of the discontinuation of anti‐calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Euro J of Neurology. Published online February 13, 2022:ene.15260. https://doi.org/10.1111/ene.15260

45.

Schiano di Cola F, Caratozzolo S, Venturelli E, et al (2021) Erenumab discontinuation following 12-month treatment: a multicentric observational real-life study. Neurol Clin Pract. Published online July 1, 2021:https://doi.org/10.1212/CPJ.0000000000001112

46.

Gantenbein AR, Agosti R, Gobbi C et al (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study. Cephalalgia 41(11–12):1181–1186. https://doi.org/10.1177/03331024211014616CrossRefPubMedPubMedCentral

47.

Ashina M, Goadsby PJ, Reuter U et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716–1725. https://doi.org/10.1111/ene.14715CrossRefPubMedPubMedCentral

48.

49.

Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Euro J Neurol 29(5):1505–1513. https://doi.org/10.1111/ene.15260CrossRef

50.

Vernieri F, Altamura C, Brunelli N, et al (2021) Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study. Eur J Neurol. Published online December 6, 2021:ene.15197. https://doi.org/10.1111/ene.15197

51.

Peng KP, Basedau H, Oppermann T, May A (2022) Trigeminal sensory modulatory effects of galcanezumab and clinical response prediction. Pain. 2022;Publish Ahead of Print. https://doi.org/10.1097/j.pain.0000000000002614

52.

Zecca C, Cargnin S, Schankin C, et al (2022) Clinic and genetic predictors in response to erenumab. Euro J of Neurology. Published online January 21, 2022:ene.15236. https://doi.org/10.1111/ene.15236

53.

Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S (2021) Predictors of response to erenumab after 12 months of treatment. Brain Behav. 2021;11(8). https://doi.org/10.1002/brb3.2260

54.

Frattale I, Caponnetto V, Casalena A et al (2021) Association between response to triptans and response to erenumab: real-life data. J Headache Pain 22(1):1. https://doi.org/10.1186/s10194-020-01213-3CrossRefPubMedPubMedCentral

55.

Bottiroli S, De Icco R, Vaghi G et al (2021) Psychological predictors of negative treatment outcome with erenumab in chronic migraine: data from an open label long-term prospective study. J Headache Pain 22(1):114. https://doi.org/10.1186/s10194-021-01333-4CrossRefPubMed

56.

Sacco S, Braschinsky M, Ducros A et al (2020) European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 21(1):76. https://doi.org/10.1186/s10194-020-01130-5CrossRefPubMedPubMedCentral

57.

Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12(10):575–583. https://doi.org/10.1038/nrneurol.2016.124CrossRefPubMed

58.

Scheffler A, Messel O, Wurthmann S et al (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21(1):84. https://doi.org/10.1186/s10194-020-01151-0CrossRefPubMedPubMedCentral

59.

Pensato U, Baraldi C, Favoni V, et al (2022) Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache. Cephalalgia. Published online February 9, 2022:033310242110677. https://doi.org/10.1177/03331024211067791

60.

Teva Branded Pharmaceutical Products R&D, Inc (2021) A multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study comparing the efficacy and safety of 2 dose regimens (intravenous/subcutaneous and subcutaneous) of TEV-48125 versus placebo for the prevention of epidosic cluster headache. clinicaltrials.gov; 2021. Accessed 13 Apr 2022. https://clinicaltrials.gov/ct2/show/study/NCT02945046

61.

Teva Branded Pharmaceutical Products R&D, Inc (2021) A multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study comparing the efficacy and safety of 2 dose regimens (intravenous/subcutaneous and subcutaneous) of TEV-48125 versus placebo for the prevention of chronic cluster headache. clinicaltrials.gov; 2021. Accessed 13 Apr 2022. https://clinicaltrials.gov/ct2/show/nct02964338

62.

Goadsby PJ, Dodick DW, Leone M et al (2019) Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med 381(2):132–141. https://doi.org/10.1056/NEJMoa1813440CrossRefPubMed

63.

Dodick DW, Goadsby PJ, Lucas C et al (2020) Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia 40(9):935–948. https://doi.org/10.1177/0333102420905321CrossRefPubMedPubMedCentral

64.

Ruscheweyh R, Broessner G, Goßrau G et al (2020) Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: results from a retrospective case series support individual treatment attempts. Cephalalgia 40(14):1574–1584. https://doi.org/10.1177/0333102420949866CrossRefPubMedPubMedCentral

65.

H. Lundbeck (2022) A/S Interventional, randomized, double-blind, parallel-group, placebo-controlled delayed-start study to evaluate the efficacy and safety of eptinezumab in patients with episodic cluster headache. clinicaltrials.gov; 2022. Accessed 11 Apr 2022. https://clinicaltrials.gov/ct2/show/NCT04688775

66.

H. Lundbeck (2022) A/S. Interventional, open-label, fixed-dose multiple administration study to evaluate long-term treatment with eptinezumab in patients with chronic cluster headache. clinicaltrials.gov; 2022. Accessed 11 Apr 2022. https://clinicaltrials.gov/ct2/show/NCT05064397

67.

Pavlovic JM, Paemeleire K, Göbel H et al (2020) Efficacy and safety of erenumab in women with a history of menstrual migraine. J Headache Pain 21(1):95. https://doi.org/10.1186/s10194-020-01167-6CrossRefPubMedPubMedCentral

68.

Ornello R, Frattale I, Caponnetto V, De Matteis E, Pistoia F, Sacco S (2021) Menstrual headache in women with chronic migraine treated with erenumab: an observational case series. Brain Sci 11(3):370. https://doi.org/10.3390/brainsci11030370CrossRefPubMedPubMedCentral

69.

Silvestro M, Orologio I, Bonavita S et al (2021) Effectiveness and safety of CGRP-mAbs in menstrual-related migraine: a real-world experience. Pain Ther 10(2):1203–1214. https://doi.org/10.1007/s40122-021-00273-wCrossRefPubMedPubMedCentral

Titel: The ultimate guide to the anti-CGRP monoclonal antibodies galaxy
verfasst von: Davide Mascarella
Eleonora Matteo
Valentina Favoni
Sabina Cevoli
Publikationsdatum: 20.06.2022
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 9/2022
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-06199-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2022

Side effects of long-term oral anti-seizure drugs on thyroid hormones in patients with epilepsy: a systematic review and network meta-analysis

Feasibility and effect of mindfulness approach by web for chronic migraine and high-frequency episodic migraine without aura at in adolescents during and after COVID emergency: preliminary findings

A mild course of COVID-19 infection in a generalized Myasthenia gravis patient under eculizumab treatment

Stroke admissions during the COVID-19 pandemic: a single-center retrospective analysis

The use of corticosteroids in patients with COVID-19 vaccine–related cerebral venous thrombosis